Slovenia

Krka has maintained strong growth in the past nine months despite ongoing questions surrounding its significant presence in Russia and foreign currency risks linked to the rouble.

Krka insisted that its margins were “stable and high,” as the Slovenian firm reported another solid quarter.

J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.

Krka has reaffirmed its full-year financial goals after a solid start to 2024, which included 8% revenue growth for its pharmaceutical products. Generics Bulletin examines the company’s sprawling global operations.

Delivering record annual sales and profits according to preliminary financial results, Slovenia’s Krka will soon look to set up shop in India via a new company established with local big player Laurus Labs.

Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.

Slovenian firm and significant Eastern European and Central Asian player Krka has reported encouraging preliminary financial results for the first six months of the year, ahead of the imminent publication of its complete financial results.

On the back of recently-announced initiatives and alliances to bolster its biosimilars business ahead of its upcoming spinoff from parent company Novartis, Sandoz has revealed a further investment of around $90m to construct a technical development center in Slovenia.

The proposed European Health Data Space aims to enable the seamless transition of health data sharing for certain purposes across the EU. A new report highlights how national variations in data storage and budgetary constraints may affect the initiative’s success.

Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.